Abstract:Epithelial‐mesenchymal transition (EMT) is a complex process with a primordial role in cellular transformation whereby an epithelial cell transforms and acquires a mesenchymal phenotype. This transformation plays a pivotal role in tumor progression and self‐renewal, and exacerbates resistance to apoptosis and chemotherapy. EMT can be initiated and promoted by deregulated oncogenic signaling pathways, hypoxia, and cells in the tumor microenvironment, resulting in a loss‐of‐epithelial cell polarity, cell–cell adhesion, and enhanced invasive/migratory properties. Numerous transcriptional regulators, such as Snail, Slug, Twist, and ZEB1/ZEB2 induce EMT through the downregulation of epithelial markers and gain‐of‐expression of the mesenchymal markers. Additionally, signaling cascades such as Wnt/β‐catenin, Notch, Sonic hedgehog, nuclear factor kappa B, receptor tyrosine kinases, PI3K/AKT/mTOR, Hippo, and transforming growth factor‐β pathways regulate EMT whereas they are often deregulated in cancers leading to aberrant EMT. Furthermore, noncoding RNAs, tumor‐derived exosomes, and epigenetic alterations are also involved in the modulation of EMT. Therefore, the regulation of EMT is a vital strategy to control the aggressive metastatic characteristics of tumor cells. Despite the vast amount of preclinical data on EMT in cancer progression, there is a lack of clinical translation at the therapeutic level. In this review, we have discussed thoroughly the role of the aforementioned transcription factors, noncoding RNAs (microRNAs, long noncoding RNA, circular RNA), signaling pathways, epigenetic modifications, and tumor‐derived exosomes in the regulation of EMT in cancers. We have also emphasized the contribution of EMT to drug resistance and possible therapeutic interventions using plant‐derived natural products, their semi‐synthetic derivatives, and nano‐formulations that are described as promising EMT blockers.

Regulation of Epithelial–Mesenchymal Transition through SUMOylation of Transcription Factors

The Emerging Roles of SUMOylation in the Tumor Microenvironment and Therapeutic Implications

Post-Translational Modification of SUMOylation and Cancer: A Brief Review

Regulation of SUMOylation Targets Associated With Wnt/beta-Catenin Pathway

Regulation of SUMOylation Targets Associated With Wnt/β-Catenin Pathway.

The post-translational modification, SUMOylation, and cancer (Review)

SUMOylation Homeostasis in Tumorigenesis

Epigenetic Regulation of Epithelial to Mesenchymal Transition in the Cancer Metastatic Cascade: Implications for Cancer Therapy

Epigenetic Regulation of Epithelial to Mesenchymal Transition.

Crosstalk between SUMOylation and other post-translational modifications in breast cancer

SUMO and the robustness of cancer

Epigenetic Control of Epithelial-to-mesenchymal Transition and Cancer Metastasis

Regulation of SUMOylation on RNA Metabolism in Cancers

Therapeutic Potential of Targeting the SUMO Pathway in Cancer

A SUMOylation-dependent pathway regulates SIRT1 transcription and lung cancer metastasis.

Mechanism of epithelial‐mesenchymal transition in cancer and its regulation by natural compounds

The SUMO Family: Mechanisms and Implications in Thyroid Cancer Pathogenesis and Therapy

Targeted inhibition of SUMOylation: treatment of tumors

Post-transcriptional regulatory network of epithelial-to-mesenchymal and mesenchymal-to-epithelial transitions

Mechanism and regulation of epithelial–mesenchymal transition in cancer

Sumoylation As an Emerging Target in Therapeutics Against Cancer